Amyloid deposition, hypometabolism, and longitudinal cognitive decline
dc.contributor.author | Landau, Susan M. | en_US |
dc.contributor.author | Mintun, Mark A. | en_US |
dc.contributor.author | Joshi, Abhinay D. | en_US |
dc.contributor.author | Koeppe, Robert A. | en_US |
dc.contributor.author | Petersen, Ronald C. | en_US |
dc.contributor.author | Aisen, Paul S. | en_US |
dc.contributor.author | Weiner, Michael W. | en_US |
dc.contributor.author | Jagust, William J. | en_US |
dc.date.accessioned | 2012-11-07T17:04:31Z | |
dc.date.available | 2013-11-15T16:44:23Z | en_US |
dc.date.issued | 2012-10 | en_US |
dc.identifier.citation | Landau, Susan M.; Mintun, Mark A.; Joshi, Abhinay D.; Koeppe, Robert A.; Petersen, Ronald C.; Aisen, Paul S.; Weiner, Michael W.; Jagust, William J. (2012). "Amyloid deposition, hypometabolism, and longitudinal cognitive decline." Annals of Neurology 72(4): 578-586. <http://hdl.handle.net/2027.42/94245> | en_US |
dc.identifier.issn | 0364-5134 | en_US |
dc.identifier.issn | 1531-8249 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/94245 | |
dc.description.abstract | Objective: Using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) population, we examined (1) cross‐sectional relationships between amyloid deposition, hypometabolism, and cognition, and (2) associations between amyloid and hypometabolism measurements and longitudinal cognitive measurements. Methods: We examined associations between mean cortical florbetapir uptake, mean 18 F‐fluorodeoxyglucose–positron emission tomography (FDG‐PET) within a set of predefined regions, and Alzhiemer's Disease Assessment Scale (ADAS‐cog) performance in 426 ADNI participants (126 normal, 162 early mild cognitive impairment [EMCI], 85 late MCI [LMCI], 53 Alzheimer disease [AD] patients). For a subset of these (76 normal, 81 LMCI) we determined whether florbetapir and FDG‐PET were associated with retrospective decline in longitudinal ADAS‐cog measurements. Results: Twenty‐nine percent of normal subjects, 43% of EMCI patients, 62% of LMCI patients, and 77% of AD patients were categorized as florbetapir positive. Florbetapir was negatively associated with concurrent FDG and ADAS‐cog in both MCI groups. In longitudinal analyses, florbetapir‐positive subjects in both normal and LMCI groups had greater ongoing ADAS‐cog decline than those who were florbetapir negative. However, in normal subjects, florbetapir positivity was associated with greater ADAS‐cog decline than FDG, whereas in LMCI, FDG positivity was associated with greater decline than florbetapir. Interpretation: Although both hypometabolism and β‐amyloid (Aβ) deposition are detectable in normal subjects and all diagnostic groups, Aβ showed greater associations with cognitive decline in normal participants. In view of the minimal cognitive deterioration overall in this group, this suggests that amyloid deposition has an early and subclinical impact on cognition that precedes metabolic changes. At moderate and later stages of disease (LMCI/AD), hypometabolism becomes more pronounced and more closely linked to ongoing cognitive decline. ANN NEUROL 2012;72:578–586 | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.title | Amyloid deposition, hypometabolism, and longitudinal cognitive decline | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Psychiatry | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Radiology, University of Michigan Medical School, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA | en_US |
dc.contributor.affiliationother | Veterans Affairs and University of California at San Francisco, San Francisco, CA | en_US |
dc.contributor.affiliationother | Department of Neurosciences, University of California at San Diego, San Diego, CA | en_US |
dc.contributor.affiliationother | Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN | en_US |
dc.contributor.affiliationother | Helen Wills Neuroscience Institute, University of California at Berkeley, Berkeley, CA | en_US |
dc.contributor.affiliationother | Avid Radiopharmaceuticals, Inc., Philadelphia, PA | en_US |
dc.contributor.affiliationother | 118 Barker Hall MC #3190, UC Berkeley, Berkeley, CA 94720‐3190 | en_US |
dc.contributor.affiliationother | School of Public Health, University of California at Berkeley, Berkeley, CA | en_US |
dc.identifier.pmid | 23109153 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/94245/1/23650_ftp.pdf | |
dc.identifier.doi | 10.1002/ana.23650 | en_US |
dc.identifier.source | Annals of Neurology | en_US |
dc.identifier.citedreference | Shimada H, Ataka S, Takeuchi J, et al. Pittsburgh compound B‐negative dementia: a possibility of misdiagnosis of patients with non‐Alzheimer disease‐type dementia as having AD. J Geriatr Psychiatry Neurol 2011; 24: 123 – 126. | en_US |
dc.identifier.citedreference | Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C‐PIB PET study. Neurology 2009; 73: 754 – 760. | en_US |
dc.identifier.citedreference | Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119 – 128. | en_US |
dc.identifier.citedreference | Forster S, Grimmer T, Miederer I, et al. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry 2012; 71: 792 – 797. | en_US |
dc.identifier.citedreference | Ewers M, Insel P, Jagust WJ, et al. CSF biomarker and PIB‐PET‐derived beta‐amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex, first published online October 29, 2011 doi:10.1093/cercor/bhr271. | en_US |
dc.identifier.citedreference | Kadir A, Almkvist O, Forsberg A, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 2012; 33: 198.e1 – 198.e14. | en_US |
dc.identifier.citedreference | Ossenkoppele R, Tolboom N, Foster‐Dingley JC, et al. Longitudinal imaging of Alzheimer pathology using [(11)C]PIB, [(18)F]FDDNP and [(18)F]FDG PET. Eur J Nucl Med Mol Imaging 2012; 39: 990 – 1000. | en_US |
dc.identifier.citedreference | Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir‐PET for imaging beta‐amyloid pathology. JAMA 2011; 305: 275 – 283. | en_US |
dc.identifier.citedreference | McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939 – 944. | en_US |
dc.identifier.citedreference | Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356 – 1364. | en_US |
dc.identifier.citedreference | Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005; 26: 839 – 851. | en_US |
dc.identifier.citedreference | Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009; 73: 1193 – 1199. | en_US |
dc.identifier.citedreference | Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG‐PET measures of decline in AD and MCI. Neurobiol Aging 2011; 32: 1207 – 1218. | en_US |
dc.identifier.citedreference | Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects. J Nucl Med 2012; 53: 378 – 384. | en_US |
dc.identifier.citedreference | Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal‐mediated beta‐amyloid deposition in elderly subjects. Brain 2009; 132: 1310 – 1323. | en_US |
dc.identifier.citedreference | Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275 – 1283. | en_US |
dc.identifier.citedreference | Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446 – 452. | en_US |
dc.identifier.citedreference | Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011; 68: 1404 – 1411. | en_US |
dc.identifier.citedreference | Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007; 68: 501 – 508. | en_US |
dc.identifier.citedreference | Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG‐PET in the differential diagnosis of AD and FTLD. Neurology 2011; 77: 2034 – 2042. | en_US |
dc.identifier.citedreference | Massoud F, Devi G, Stern Y, et al. A clinicopathological comparison of community‐based and clinic‐based cohorts of patients with dementia. Arch Neurol 1999; 56: 1368 – 1373. | en_US |
dc.identifier.citedreference | Ranginwala NA, Hynan LS, Weiner MF, White CL III. Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years. Am J Geriatr Psychiatry 2008; 16: 384 – 388. | en_US |
dc.identifier.citedreference | Lim A, Tsuang D, Kukull W, et al. Clinico‐neuropathological correlation of Alzheimer's disease in a community‐based case series. J Am Geriatr Soc 1999; 47: 564 – 569. | en_US |
dc.identifier.citedreference | Pearl GS. Diagnosis of Alzheimer's disease in a community hospital‐based brain bank program. South Med J 1997; 90: 720 – 722. | en_US |
dc.identifier.citedreference | Chetelat G, Villemagne VL, Pike KE, et al. Relationship between Memory Performance and beta‐Amyloid Deposition at Different Stages of Alzheimer's Disease. Neurodegener Dis 2012; 10: 141 – 144. | en_US |
dc.identifier.citedreference | Pike KE, Ellis KA, Villemagne VL, et al. Cognition and beta‐amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia 2011; 49: 2384 – 2390. | en_US |
dc.identifier.citedreference | Rodrigue KM, Kennedy KM, Devous MD Sr, et al. β‐Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 2012; 78: 387 – 395. | en_US |
dc.identifier.citedreference | Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132 ( pt 5 ): 1355 – 1365. | en_US |
dc.identifier.citedreference | Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid‐beta measured by [11C]PiB. Neurology 2010; 74: 807 – 815. | en_US |
dc.identifier.citedreference | Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late‐onset Alzheimer's dementia. Proc Natl Acad Sci U S A 2004; 101: 284 – 289. | en_US |
dc.identifier.citedreference | Petersen RC. Conceptual overview. In: Petersen RC, ed. Mild cognitive impairment: aging to alzheimer's disease. New York, NY: Oxford University Press, 2003: 1 – 14. | en_US |
dc.identifier.citedreference | Mosconi L, Mistur R, Switalski R, et al. FDG‐PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009; 36: 811 – 822. | en_US |
dc.identifier.citedreference | Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow‐up study. Eur J Nucl Med Mol Imaging 2003; 30: 1104 – 1113. | en_US |
dc.identifier.citedreference | Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010; 75: 230 – 238. | en_US |
dc.identifier.citedreference | Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid‐beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009; 66: 1476 – 1481. | en_US |
dc.identifier.citedreference | Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69: 181 – 192. | en_US |
dc.identifier.citedreference | Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta‐amyloid measures and magnetic resonance imaging atrophy both predict time‐to‐progression from mild cognitive impairment to Alzheimer's disease. Brain 2010; 133: 3336 – 3348. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.